Patient perspectives on achieving treat-to-target goals: A critical examination of patient-reported outcomes

Arthritis Care and Research

Volumn 65, Issue 10, 2013, Pages 1707-1712

  Curtis, Jeffrey R ^a   Shan, Ying ^b   Harrold, Leslie ^b   Zhang, Jie ^a   Greenberg, Jeffrey D ^c   Reed, George W ^b  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b UNIVERSITY OF MASSACHUSETTS   (United States)

^c NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DISEASE MODIFYING ANTIRHEUMATIC DRUG; GLUCOCORTICOID; METHOTREXATE; NARCOTIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISONE; TUMOR NECROSIS FACTOR INHIBITOR;

ACHIEVEMENT; ADULT; ARTICLE; BIOLOGICAL THERAPY; CLINICAL EXAMINATION; CORTICOSTEROID THERAPY; DISABILITY; DISEASE ACTIVITY; FATIGUE; FEMALE; FOLLOW UP; GLOBAL ASSESSMENT OF FUNCTIONING; HEALTH ASSESSMENT QUESTIONNAIRE; HUMAN; MAJOR CLINICAL STUDY; MALE; MOTIVATION; OUTCOME ASSESSMENT; PAIN; PATIENT REPORTED OUTCOME; REMISSION; RHEUMATOID ARTHRITIS; SCORING SYSTEM; VISUAL ANALOG SCALE;

ADULT; AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL PRODUCTS; DISABILITY EVALUATION; DISEASE PROGRESSION; FEMALE; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; LEAST-SQUARES ANALYSIS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PAIN MEASUREMENT; PATIENTS; PERCEPTION; PREDICTIVE VALUE OF TESTS; REMISSION INDUCTION; SELF REPORT; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME;

EID: 84885017573     PISSN: 2151464X     EISSN: 21514658     Source Type: Journal    
DOI: 10.1002/acr.22048     Document Type: Article

References (19)

1. Smolen JS, Aletaha D, Bijlsma JW, Breedveld FC, Boumpas D, Burmester G, et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 2011; 69: 631-7.
2. Vermeer M, Kuper HH, Bernelot Moens HJ, Hoekstra M, Posthumus MD, van Riel PL, et al. Adherence to a treat-to-target strategy in early rheumatoid arthritis: results of the DREAM remission induction cohort. Arthritis Res Ther 2012; 14: R254.
3. Barton JL, Imboden J, Graf J, Glidden D, Yelin EH, Schillinger D,. Patient-physician discordance in assessments of global disease severity in rheumatoid arthritis. Arthritis Care Res (Hoboken) 2010; 62: 857-64.
4. Leeb BF, Andel I, Leder S, Leeb BA, Rintelen B,. The patient's perspective and rheumatoid arthritis disease activity indexes. Rheumatology (Oxford) 2005; 44: 360-5.
5. Nicolau G, Yogui MM, Vallochi TL, Gianini RJ, Laurindo IM, Novaes GS,. Sources of discrepancy in patient and physician global assessments of rheumatoid arthritis disease activity. J Rheumatol 2004; 31: 1293-6.
6. Van Tuyl LH, Boers M,. Patient's global assessment of disease activity: what are we measuring? [editorial]. Arthritis Rheum 2012; 64: 2811-3.
7. Studenic P, Smolen JS, Aletaha D,. Near misses of ACR/EULAR criteria for remission: effects of patient global assessment in Boolean and index-based definitions. Ann Rheum Dis 2012; 71: 1702-5.
8. Studenic P, Radner H, Smolen JS, Aletaha D,. Discrepancies between patients and physicians in their perceptions of rheumatoid arthritis disease activity. Arthritis Rheum 2012; 64: 2814-23.
9. Dougados M, Nataf H, Steinberg G, Rouanet S, Falissard B,. Relative importance of doctor-reported outcomes vs patient-reported outcomes in DMARD intensification for rheumatoid arthritis: the DUO study. Rheumatology (Oxford) 2013; 52: 391-9.
10. Wolfe F, Michaud K,. Resistance of rheumatoid arthritis patients to changing therapy: discordance between disease activity and patients' treatment choices. Arthritis Rheum 2007; 56: 2135-42.
11. Kremer JM,. The CORRONA database. Autoimmun Rev 2006; 5: 46-54.
12. Singh JA, Furst DE, Bharat A, Curtis JR, Kavanaugh AF, Kremer JM, et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) 2012; 64: 625-39.
13. Zhang J, Shan Y, Reed G, Kremer J, Greenberg JD, Baumgartner S, et al. Thresholds in disease activity for switching biologics in rheumatoid arthritis patients: experience from a large US cohort. Arthritis Care Res (Hoboken) 2011; 63: 1672-9.
14. Greenberg JD, Harrold LR, Bentley MJ, Kremer J, Reed G, Strand V,. Evaluation of composite measures of treatment response without acute-phase reactants in patients with rheumatoid arthritis. Rheumatology (Oxford) 2009; 48: 686-90.
15. Van Gestel AM, Haagsma CJ, van Riel PL,. Validation of rheumatoid arthritis improvement criteria that include simplified joint counts. Arthritis Rheum 1998; 41: 1845-50.
16. Wells GA, Tugwell P, Kraag GR, Baker PR, Groh J, Redelmeier DA,. Minimum important difference between patients with rheumatoid arthritis: the patient's perspective. J Rheumatol 1993; 20: 557-60.
17. Dworkin RH, Turk DC, Wyrwich KW, Beaton D, Cleeland CS, Farrar JT, et al. Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. J Pain 2008; 9: 105-21.
18. Aletaha D, Nell VP, Stamm T, Uffmann M, Pflugbeil S, Machold K, et al. Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score. Arthritis Res Ther 2005; 7: R796-806.
19. Curtis JR, Jain A, Askling J, Bridges SL Jr, Carmona L, Dixon W, et al. A comparison of patient characteristics and outcomes in selected European and U.S. rheumatoid arthritis registries. Semin Arthritis Rheum 2010; 40: 2-14.e1.